Thus, although animal experiments showed that melanoma cell‐derived EV PD‐L2 could influence the efficacy of ICIs, the exact cellular origins of PD‐L2 in circulating EVs within patients require further investigation. The gene discussed is PDCD1LG2; the disease is melanoma.